An Open-Label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR gene amplification

Trial Profile

An Open-Label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR gene amplification

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Neratinib (Primary) ; Fulvestrant; Paclitaxel
  • Indications Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Uterine cancer
  • Focus Therapeutic Use
  • Acronyms BASKET; SUMMIT
  • Sponsors Puma Biotechnology
  • Most Recent Events

    • 12 Dec 2017 Planned number of patients changed from 292 to 392.
    • 02 Jun 2017 Results (n=3) evaluating response and genomic profiles of patients from this and one other trial presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Apr 2017 According to a Puma Biotechnology media release, results (n=141) from this trial were presented at the American Association for Cancer Research (AACR) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top